We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.09%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.54B
AUM Growth
-$145M
(-3.1%)
Cap. Flow
-$1.24B
Cap. Flow
% of AUM
-27.38%
Top 10 Holdings %
Top 10 Hldgs %
54.9%
Holding
112
New
14
Increased
17
Reduced
7
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bio-Rad Laboratories Class A
BIO
|
+$67.1M |
| 2 |
Surgery Partners
SGRY
|
+$52.5M |
| 3 |
Integra LifeSciences
IART
|
+$47.4M |
| 4 |
Centene
CNC
|
+$42.6M |
| 5 |
AdaptHealth
AHCO
|
+$30.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMED
Amedisys
AMED
|
+$164M |
| 2 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$36.8M |
| 3 |
NewAmsterdam Pharma
NAMS
|
+$30.1M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$28.5M |
| 5 |
Cogent Biosciences
COGT
|
+$27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.01% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Structure Therapeutics
GPCR
$3.45B
| $31.7M | 0.7% |
627,813
| – | – |
|
|
RYZB
27
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $25.7M | 0.57% |
+1,159,126
| New | +$24.3M |
|
28
DocGo
DCGO
$64.3M
| $25.4M | 0.56% |
4,764,000
+1,705,000
| +56% | +$13.8M |
|
29
BioCryst Pharmaceuticals
BCRX
$2.36B
| $23.3M | 0.51% |
3,286,000
+1,964,000
| +149% | +$14.1M |
|
30
Edgewise Therapeutics
EWTX
$4.28B
| $22.5M | 0.5% |
3,933,137
| – | – |
|
31
Insulet
PODD
$11.4B
| $20.3M | 0.45% |
+127,000
| New | +$28.4M |
|
32
Disc Medicine
IRON
$2.91B
| $20.2M | 0.45% |
430,000
| – | – |
|
33
Alignment Healthcare
ALHC
$4.26B
| $19.1M | 0.42% |
2,747,015
+905,015
| +49% | +$5.46M |
|
34
Roivant Sciences
ROIV
$24.8B
| $18.7M | 0.41% |
1,604,487
+249,513
| +18% | +$2.82M |
|
35
Caribou Biosciences
CRBU
$164M
| $16.7M | 0.37% |
+3,500,000
| New | +$21.7M |
|
36
Castle Biosciences
CSTL
$733M
| $16M | 0.35% |
+946,620
| New | +$16.6M |
|
|
DAWN
37
DELISTED
Day One Biopharmaceuticals
DAWN
| $15.6M | 0.34% |
1,269,992
| – | – |
|
38
Viking Therapeutics
VKTX
$4.31B
| $14.2M | 0.31% |
1,279,000
+154,000
| +14% | +$2.2M |
|
39
Tarsus Pharmaceuticals
TARS
$2.61B
| $13.4M | 0.3% |
+754,042
| New | +$13.3M |
|
40
Verastem
VSTM
$530M
| $12.5M | 0.28% |
1,538,461
| – | – |
|
41
Denali Therapeutics
DNLI
$3.7B
| $12.3M | 0.27% |
594,989
| – | – |
|
42
QuidelOrtho
QDEL
$1.19B
| $11M | 0.24% |
+150,000
| New | +$12M |
|
|
43
Cogent Biosciences
COGT
$6.68B
| $10.6M | 0.23% |
1,089,345
-2,277,000
| -68% | -$27M |
|
44
Pulmonx
LUNG
$59.1M
| $10.5M | 0.23% |
1,017,958
-46,327
| -4% | -$537K |
|
|
RVNC
45
DELISTED
Revance Therapeutics, Inc.
RVNC
| $9.98M | 0.22% |
870,000
| – | – |
|
|
VIGL
46
DELISTED
Vigil Neuroscience
VIGL
| $9.85M | 0.22% |
1,827,400
-224,610
| -11% | -$1.55M |
|
|
BCYC
47
Bicycle Therapeutics
BCYC
$294M
| $9.02M | 0.2% |
+448,753
| New | +$10.3M |
|
48
Tango Therapeutics
TNGX
$4.65B
| $8.94M | 0.2% |
+793,729
| New | +$4.84M |
|
49
Prime Medicine
PRME
$565M
| $8.45M | 0.19% |
885,314
| – | – |
|
50
4D Molecular Therapeutics
FDMT
$575M
| $8.27M | 0.18% |
650,000
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2023 Portfolio in Review
As of Q3 2023, Deerfield Management held 112 positions worth $4.54B, down 3.1% from $4.68B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Deerfield Management withdrew a net $1.24B in Q3 2023, closing 24 positions and reducing 7 holdings. Its most notable exit was Amedisys, an estimated $164M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 68% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Bio-Rad Laboratories Class A worth $62.4M.
- Deerfield Management's largest Q3 2023 buy was Bio-Rad Laboratories Class A: 173,947 shares worth $62.4M.
- Deerfield Management added most to Centene in Q3 2023, an estimated $42.6M increase.
- Deerfield Management's biggest Q3 2023 reduction was Cogent Biosciences, cutting an estimated $27M.
- Deerfield Management fully exited Amedisys in Q3 2023, selling an estimated $164M.
- Deerfield Management's ten largest holdings make up 55% of its $4.54B portfolio in Q3 2023.
- Deerfield Management opened 14 new positions and closed 24 in Q3 2023.
- Deerfield Management's portfolio value fell 3.1% quarter-over-quarter to $4.54B.
Based on Deerfield Management's 13F filing for Q3 2023, filed 14 Nov 2023.